THURSDAY, Sept. 5, 2024 -- For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and...
Vous n'êtes pas connecté
Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based on evidence from the INDIGO clinical trial, a global phase 3, double-blinded, randomised clinical trial, vorasidenib more than doubled progression-free survival and delayed the need for treatment with radiation and chemotherapy for patients with Grade 2 [...]
THURSDAY, Sept. 5, 2024 -- For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and...
Doctors advised the model to undergo a mastectomy with radiation, chemotherapy, hormone therapy and a breast reconstruction.
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
Following surgery, doctors advised the model to undergo a mastectomy with radiation, chemotherapy and a breast reconstruction.
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Relay Therapeutics, Inc., a clinical─stage precision medicine company transforming the drug discovery process by combining leading─edge...
The first two blood cancer patients in a US-based trial, who had suffered relapses despite having treatment, have now been in remission for up to 120...
Breast cancer is the leading cancer among Indian women, especially in urban regions due to lifestyle shifts. Early detection challenges contribute to...
Patients born with genetic blindness experienced significant visual improvements after a single treatment with gene therapy developed at the...